Monitoring the effectiveness of hypothermia in perinatal asphyxia infants by urinary S100B levels

Cooperative Multitask against Brain Injury of Neonates (CoMBINe) Group

Research output: Contribution to journalArticle

Abstract

Background Perinatal asphyxia is a major cause of mortality and morbidity in neonates: The aim of the present study was to investigate, by means of longitudinal assessment of urinary S100B, the effectiveness of hypothermia, in infants complicated by perinatal asphyxia and hypoxic-ischemic encephalopathy. Methods We performed a retrospective case-control study in 108 asphyxiated infants, admitted to nine tertiary departments for neonatal intensive care from January 2004 to July 2017, of whom 54 underwent hypothermia treatment and 54 did not. The concentrations of S100B protein in urine were measured using an immunoluminometric assay at first urination and 4, 8, 12, 16, 20, 24, 48, 72, 96, 108 and 120 h after birth. The results were correlated with the achievement of S100B levels within normal ranges at 72 h from hypothermia treatment. Routine laboratory parameters, longitudinal cerebral function monitoring, cerebral ultrasound and neurologic patterns were assessed according to standard protocols. Results Higher S100B concentrations were found in hypothermia-treated infants in both moderate (up to 12 h) and severe (up to 24 h) hypoxic-ischemic encephalopathy. S100B levels returned to normal ranges starting from 20 h of hypothermia treatment in moderate and from 36 h in severe hypoxic-ischemic encephalopathy. Conclusions The present results offer additional support to the usefulness of longitudinal neuro-biomarkers monitoring in asphyxiated infants treated by hypothermia. The pattern of S100B concentrations during hypothermia supports the need for further investigations aimed at reconsidering the time-window for patient recruitment and treatment, and the optimal duration of the cooling and rewarming phases of the hypothermia procedure.

Original languageEnglish
JournalClinical Chemistry and Laboratory Medicine
DOIs
Publication statusPublished - Jun 26 2019

Fingerprint

Hypothermia
Asphyxia
Monitoring
Brain Hypoxia-Ischemia
Reference Values
Neonatal Intensive Care
Rewarming
Urination
Biomarkers
Therapeutics
Patient Selection
Nervous System
Case-Control Studies
Assays
Ultrasonics
Urine
Parturition
Newborn Infant
Cooling
Morbidity

Cite this

Monitoring the effectiveness of hypothermia in perinatal asphyxia infants by urinary S100B levels. / Cooperative Multitask against Brain Injury of Neonates (CoMBINe) Group.

In: Clinical Chemistry and Laboratory Medicine, 26.06.2019.

Research output: Contribution to journalArticle

@article{34e3ceaa318b4cceb804429363b368fe,
title = "Monitoring the effectiveness of hypothermia in perinatal asphyxia infants by urinary S100B levels",
abstract = "Background Perinatal asphyxia is a major cause of mortality and morbidity in neonates: The aim of the present study was to investigate, by means of longitudinal assessment of urinary S100B, the effectiveness of hypothermia, in infants complicated by perinatal asphyxia and hypoxic-ischemic encephalopathy. Methods We performed a retrospective case-control study in 108 asphyxiated infants, admitted to nine tertiary departments for neonatal intensive care from January 2004 to July 2017, of whom 54 underwent hypothermia treatment and 54 did not. The concentrations of S100B protein in urine were measured using an immunoluminometric assay at first urination and 4, 8, 12, 16, 20, 24, 48, 72, 96, 108 and 120 h after birth. The results were correlated with the achievement of S100B levels within normal ranges at 72 h from hypothermia treatment. Routine laboratory parameters, longitudinal cerebral function monitoring, cerebral ultrasound and neurologic patterns were assessed according to standard protocols. Results Higher S100B concentrations were found in hypothermia-treated infants in both moderate (up to 12 h) and severe (up to 24 h) hypoxic-ischemic encephalopathy. S100B levels returned to normal ranges starting from 20 h of hypothermia treatment in moderate and from 36 h in severe hypoxic-ischemic encephalopathy. Conclusions The present results offer additional support to the usefulness of longitudinal neuro-biomarkers monitoring in asphyxiated infants treated by hypothermia. The pattern of S100B concentrations during hypothermia supports the need for further investigations aimed at reconsidering the time-window for patient recruitment and treatment, and the optimal duration of the cooling and rewarming phases of the hypothermia procedure.",
author = "Iliana Bersani and Fabrizio Ferrari and Licia Lugli and Giorgio Ivani and Alessandra Conio and Bashir Moataza and Hanna Aboulgar and Hala Mufeed and Iman Iskander and Maria Kornacka and Darek Gruzfeld and Andrea Dotta and Immacolata Savarese and Natalia Chukhlantseva and Tina, {Lucia Gabriella} and Francesco Nigro and Giovanni Livolti and Fabio Galvano and Laura Serpero and Micaela Colivicchi and Patrizia Ianniello and Francesca Pluchinotta and Luigi Anastasia and Ekaterina Baryshnikova and Diego Gazzolo and {Cooperative Multitask against Brain Injury of Neonates (CoMBINe) Group}",
year = "2019",
month = "6",
day = "26",
doi = "10.1515/cclm-2018-1094",
language = "English",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH",

}

TY - JOUR

T1 - Monitoring the effectiveness of hypothermia in perinatal asphyxia infants by urinary S100B levels

AU - Bersani, Iliana

AU - Ferrari, Fabrizio

AU - Lugli, Licia

AU - Ivani, Giorgio

AU - Conio, Alessandra

AU - Moataza, Bashir

AU - Aboulgar, Hanna

AU - Mufeed, Hala

AU - Iskander, Iman

AU - Kornacka, Maria

AU - Gruzfeld, Darek

AU - Dotta, Andrea

AU - Savarese, Immacolata

AU - Chukhlantseva, Natalia

AU - Tina, Lucia Gabriella

AU - Nigro, Francesco

AU - Livolti, Giovanni

AU - Galvano, Fabio

AU - Serpero, Laura

AU - Colivicchi, Micaela

AU - Ianniello, Patrizia

AU - Pluchinotta, Francesca

AU - Anastasia, Luigi

AU - Baryshnikova, Ekaterina

AU - Gazzolo, Diego

AU - Cooperative Multitask against Brain Injury of Neonates (CoMBINe) Group

PY - 2019/6/26

Y1 - 2019/6/26

N2 - Background Perinatal asphyxia is a major cause of mortality and morbidity in neonates: The aim of the present study was to investigate, by means of longitudinal assessment of urinary S100B, the effectiveness of hypothermia, in infants complicated by perinatal asphyxia and hypoxic-ischemic encephalopathy. Methods We performed a retrospective case-control study in 108 asphyxiated infants, admitted to nine tertiary departments for neonatal intensive care from January 2004 to July 2017, of whom 54 underwent hypothermia treatment and 54 did not. The concentrations of S100B protein in urine were measured using an immunoluminometric assay at first urination and 4, 8, 12, 16, 20, 24, 48, 72, 96, 108 and 120 h after birth. The results were correlated with the achievement of S100B levels within normal ranges at 72 h from hypothermia treatment. Routine laboratory parameters, longitudinal cerebral function monitoring, cerebral ultrasound and neurologic patterns were assessed according to standard protocols. Results Higher S100B concentrations were found in hypothermia-treated infants in both moderate (up to 12 h) and severe (up to 24 h) hypoxic-ischemic encephalopathy. S100B levels returned to normal ranges starting from 20 h of hypothermia treatment in moderate and from 36 h in severe hypoxic-ischemic encephalopathy. Conclusions The present results offer additional support to the usefulness of longitudinal neuro-biomarkers monitoring in asphyxiated infants treated by hypothermia. The pattern of S100B concentrations during hypothermia supports the need for further investigations aimed at reconsidering the time-window for patient recruitment and treatment, and the optimal duration of the cooling and rewarming phases of the hypothermia procedure.

AB - Background Perinatal asphyxia is a major cause of mortality and morbidity in neonates: The aim of the present study was to investigate, by means of longitudinal assessment of urinary S100B, the effectiveness of hypothermia, in infants complicated by perinatal asphyxia and hypoxic-ischemic encephalopathy. Methods We performed a retrospective case-control study in 108 asphyxiated infants, admitted to nine tertiary departments for neonatal intensive care from January 2004 to July 2017, of whom 54 underwent hypothermia treatment and 54 did not. The concentrations of S100B protein in urine were measured using an immunoluminometric assay at first urination and 4, 8, 12, 16, 20, 24, 48, 72, 96, 108 and 120 h after birth. The results were correlated with the achievement of S100B levels within normal ranges at 72 h from hypothermia treatment. Routine laboratory parameters, longitudinal cerebral function monitoring, cerebral ultrasound and neurologic patterns were assessed according to standard protocols. Results Higher S100B concentrations were found in hypothermia-treated infants in both moderate (up to 12 h) and severe (up to 24 h) hypoxic-ischemic encephalopathy. S100B levels returned to normal ranges starting from 20 h of hypothermia treatment in moderate and from 36 h in severe hypoxic-ischemic encephalopathy. Conclusions The present results offer additional support to the usefulness of longitudinal neuro-biomarkers monitoring in asphyxiated infants treated by hypothermia. The pattern of S100B concentrations during hypothermia supports the need for further investigations aimed at reconsidering the time-window for patient recruitment and treatment, and the optimal duration of the cooling and rewarming phases of the hypothermia procedure.

U2 - 10.1515/cclm-2018-1094

DO - 10.1515/cclm-2018-1094

M3 - Article

C2 - 30753152

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

ER -